MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab

Trial Profile

MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 02 Oct 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.
    • 02 Oct 2017 Planned primary completion date changed from 30 Jun 2017 to 31 Dec 2017.
    • 17 Sep 2016 Results of interim analysis (n=162) of czech cohort was presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top